| Assessment Status | Rapid Review Complete |
| HTA ID | 23013 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
| Assessment Process | |
| Rapid review commissioned | 03/03/2023 |
| Rapid review completed | 21/04/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations. December 2023
